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ITSN1 adaptor/scaffold protein takes part in a variety of physiological and pathological cellular processes. It 
has a complex expression regulation and many protein partners. Aim. Characterization of the ITSN1 functio­
ning and expression control is important for understanding its role in cell. Methods. Bioinformatic analysis, 
semi­quantitative expression analysis by RT­PCR, immunoprecipitation. Results. We have described and ana­
lyzed the ITSN1 promoter regions, detected ITSN1 alternatively spliced isoforms at mRNA and protein levels 
in different cancer specimens. Using different bioinformatic servers, we have identified the sites for miRNA 
binding and analyzed the sites for serine, threonine and tyrosine phosphorylation of the ITSN1 protein. 
Conclusions. We have obtained new data on the ITSN1 expression in pathology. We have also shown the pos­
sibility of ITSN1 expression regulation by miRNA and phosphorylation of serine, threonine and tyrosine. 
K e y w o r d s: ITSN1, bidirectional promoter, alternative splicing, miRs, phosphorylation.
Introduction
ITSN1 is a multifunctional scaffold protein that is 
implicated in many cellular processes such as clath­
rin­ and caveolin­mediated endocytosis, exocytosis, 
MAP kinase signaling, actin cytoskeleton rearrange­
ments, membrane remodeling, etc. The ITSN1 gene 
is localized at chromosome 21. It was shown that 
ITSN1 is involved in such neurodegenerative pa­
thologies as the Down’s syndrome, Alzheimer’s and 
Huntington’s diseases [1–3]. ITSN1 takes part in mi­
gration and invasion of human glioma cells and is 
localized in invadopodia, actin­rich protrusions that 
drive invasion in cancer cells [4, 5]. Three main 
ITSN1 isoforms are produced in human: long iso­
form ITSN1-L expressed mostly in nervous system, 
short isoform ITSN1-S and ITSN1-22a isoform 
which are ubiquitously expressed. ITSN1 is an adap­
tor protein with unique multidomain structure. 
ITSN1­L consists of two N­terminal EH domains 
(EH1 and EH2), coiled-coil region (CCR), five Src 
homology 3 domains (SH3A­E), Dbl homology 
(DH), pleckstrin homology (PH), and C2 domain. 
EH domains, CCR and SH3 domains interact with 
specific protein motifs: EH domains bind NPF mo­
tifs; α-helix regions form dimers; SH3 domains bind 
proline­rich motifs (PxxP). DH domain is a guanine 
nucleotide exchange factor which activates a small 
GTPase Cdc42 from the Rho family. The main func­
tion of PH domain is considered to be the regulation 
of the DH domain and membrane localization of the 
protein via phosphoinositides binding [6]. However, 
the ITSN1 PH domain binds phosphoinositides but it 
neither influences guanine nucleotide exchange by 
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DH nor, neither determines the subcellular localiza­
tion of the protein [6, 7]. The C2 domain is thought 
to take part in Ca2+­dependent phospholipid bin­
ding [8].
Due to the multiple alternative splicing events all 
other ITSN1 isoforms lack some domains or several 
amino acid residues. For instance, the short isoform 
ITSN1­S lacks the DH, PH and C2 domains and 
therefore does not have any enzymatic activity.
The majority of ITSN1 functions is performed by 
binding to its protein partners. At the moment, more 
than thirty ITSN1 partners are discovered, and this 
list is permanently increasing as well as the list of 
ITSN1­related processes. Regarding the complexity 
of the ITSN1 interactome, the regulation of ITSN1 
gene expression and functioning is quite sophisti­
cated and is fulfilled with the variety of mechanisms 
both at transcriptional and post­transcriptional levels 
[9, 10].
Materials and Methods
Bioinformatical analysis
For the Bioinformatical analysis we used GeneBank 
(http://www.ncbi.nlm.nih.gov/) and PhosphoSitePlus 
(http://www.phosphosite.org/homeAction.action) 
databases and the following servers and online utili­
ties: UCSC Genome Browser on Human Dec. 2013 
(GRCh38/hg38) Assembly (http://genome.ucsc.edu/
cgi­bin/hgTracks?db=hg38&lastVirtModeType=def
ault&lastVirtModeExtraState=&virtModeType=de­
fault&virtMode=0&nonVirtPosition=&position=ch
r21%3A33641275­33643785&hgsid=497171239_
N C 3 k 6 O a F O r w O d e B e W s 9 R x A J n 2 q j 8 ) , 
RepeatМasker (http://www.repeatmasker.org/), 
TargetScan (http://www.targetscan.org/vert_71/), 
MicroRNA.org (http://www.microrna.org/microrna/
getGeneForm.do), RegRNA 2.0 (http://regrna2.mbc.
nctu.edu.tw/index.html).
RNA isolation and RT-PCR 
Total RNA from human tissues was isolated as de­
scribed previously [11]. cDNA was synthesized from 
1 to 5 μg of total RNA using oligo(dT18) primer and 
RevertAid H Minus Reverse Transcriptase («Thermo 
Scientific», USA). Five percent of the cDNA ob­
tained was used as a template for PCR as described 
previously [11]. The following oligonucleotides 
were used for the expression analysis of transcripts 
generated from an alternative promoter: 
20 exon frw 2566­agtcatggttaaaggggaatgg­2587; 
23 exon rev 3166­aactcgagcttgtagacttccttatg­3184; 
23 exon frw 3112­gtggtggtttggaggagttcaagg­3135; 
22 exon frw 2583­gcacgaatgagaaaccagaaacgg­2606; 
22a exon rev 2891­gactttgacagctagggcttcgga­2868; 
27 exon rev 3530­tggcggtgtatgaggcaataac­3509; 
33 exon frw 4160­gcgctgagagtccgcaagaagat­4182; 
34 exon frw 4394­ctgaagcctatgcaacgggtaac­4416; 
39 exon rev 5122­gttgctctttcctagtgaccgac­5100; 
41 exon rev 5307­atctccgtccgacccaaaaaatc­5285;
frw GAPDH 5′-tgaaggtcggagtcaacggatttggt-3′; 
rev GAPDH 5′-catgtgggccatgaggtccaccac-3′; 
frw β-actin 5′-gaaatcgtgcgtgacattaag-3′; 
rev β-actin 5′-aagcatttgcggtggacgatggag-3′.
Nucleotide positions for oligonucleotides are 
based on the ITSN1-L, ITSN1-S and ITSN1-22a 
cDNA s (GenBank accession numbers NM_003024.2, 
NM_001001132.1 and DQ386455).
Cell culture, transfection  
and immunoprecipitation
MDA­MB­231 cell lines were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented 
with 10 % fetal bovine serum, 50 U/ml penicillin 
and 100 μg/ml streptomycin. The cells were tran­
siently transfected with PEI (polyethyleneimine) ac­
cording to the manufacturer’s instructions and pro­
cessed 24 h after transfection. For immunoprecipita­
tion (IP), the cells were lysed in IP buffer (20mM 
Tris­HCl pH 7.4, 150mM NaCl, 0.5 % Nonidet P40, 
10 % glycerol, 2 mM EDTA and protease inhibitor 
cocktail). The lysates were incubated with antibod­
ies and protein A/G PLUS­Agarose («Santa Cruz 
Biotechnology», USA) prewashed in IP buffer. After 
incubation for 3 h at +4 °C, the beads were washed 
three times with IP buffer. Bound proteins were elut­
ed by boiling in Laemmli sample buffer and then 
analyzed by SDS­PAGE and Western blotting.
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Antibodies
The mouse polyclonal antibodies against the DH­PH 
domains of human ITSN1 (anti­ITSN1­DH) were 
produced in mouse immunized with recombinant 
His­tagged protein comprising amino acid residues 
1240­1575 of human ITSN1­L. The rabbit poly­
clonal antibodies against the EH2 domain of human 
ITSN1 (anti­ITSN1­EH2) were described previous­
ly [12]. The secondary horseradish peroxidase­la­
beled anti­rabbit antibodies were purchased from 
Promega.
Results and Discussion
Promoter regions of human ITSN1 gene
The ITSN1 gene has 246826 bp (NG_029504.1) and 
is localized on chromosome 21 locus q22.1­q22.2. 
The gene is comprised of 42 exons which influence 
the amino acid composition of the protein molecule. 
The expression regulation of ITSN1 at the transcrip­
tional level is performed by transcription from two 
different promoters and the generation of a vast ma­
jority of alternatively spliced mRNA isoforms. The 
main ITSN1 promoter, which gives rise to the most 
mRNAs, is a bidirectional one. These promoters are 
present in head­to­head class of genes whose TSS 
(Transcription Start Site) are located at the distance 
from 0 to 2000 bp. About 10 % of protein­coding 
genes are bidirectional in mammals. Furthremore, it 
was observed that many genes that are transcribed 
from bidirectional promoters possess functions or 
are involved in the same processes such as DNA 
reparation, chromatin stability etc. [13]. Recently, 
Yang et al. have explored the biological implication 
of the control of genome stability by bidirectional 
promoters and showed a high enrichment of bidirec­
tional promoters in genes strongly associated with 
breast and ovarian cancer [14]. Trinklein et al. ana­
lyzed TSS of 23752 human genes and revealed that 
TSS of 1352 gene pairs (11 %) were localized less 
than 1 kb from each other. Besides, the 5’­ends of 
315 pairs (23 %) were partially overlapped, whereas 
in the majority of bidirectional promoters (67 %) 
which did not overlap the distance between TSS was 
less than 300 bp. After the functional analysis in dif­
ferent cell lines it was shown that 90 % of the ana­
lyzed promoters were active in both directions, and 
only 10 % were active in only one direction. Most 
bidirectional promoters that were analyzed in the 
study of Trinklein et al. are CpG­rich, 77 % of them 
have CpG islands and only 8 % have TATA­sequence 
compared to 38 % and 28 % of unidirectional pro­
moters respectively [15]. Bidirectional promoters 
containing TATA boxes consistently show an asym­
metrical distribution favoring one TSS over the other 
[16]. The presence of DPE, Inr and BRE elements 
does not significally differ in bidirectional and unidi­
rectional promoters [15–18]. According to another 
study, the CpG islands were found to be more preva­
lent in bidirectional (90 %) promoters as opposed to 
unidirectional ones (45 %). Moreover, it was shown 
that CpG islands of bidirectional promoters differ 
from these of unidirectional promoters and are more 
functional [16]. Neuron-specific genes are poor in 
bidirectional promoters, however, specific bidirec­
tional promoters were found for nervous tissue 
(NBiPs). Novel bidirectional promoters showing di­
vergent transcription of the novel and potentially 
brain-specific lncRNAs (long non-coding RNAs), 
are highly enriched in neuronal genes [19]. 
Previously, several authors have shown that bidirec­
tional promoters are the major source of gene activa­
tion­associated non­coding RNAs in different cells 
in mammals [20].
The distance between the TSS of ITSN1 and 
CRYZL1, which are annotated in GeneBank, is 623 bp 
(Fig. 1). Thus, these genes are in the head-to-head po­
sition at the distance less than 2000 bp that meet the 
requirements of the bidirectional promoter. Trinklein 
et al. in their work [15] also defined the promoter of 
the gene pair ITSN1/CRYZL1 as a bidirectional, but 
the DNA fragment they explored corresponds to the 
incomplete promoter region of ITSN1/CRYZL1, and 
does not cover the part of CRYZL1 gene. The explored 
fragment was 201 bp long and located 10 bp to the 
annotated TSS of ITSN1 gene (Fig. 1) [15].
The ITSN1/CRYZL1 promoter is GC­rich and has 
no TATA­boxes. Using the UCSC Genome Browser 
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on Human Dec. 2013 (GRCh38/hg38) Assembly we 
have identified a CpG island which comprises 196 bp 
of the exon 1 and 773 bp of the intron 1 of ITSN1 
gene. CpG­island association is characteristic for bi­
directional promoters. CRYZL1 also has a CpG­
island which comprises exon 1 and a part of intron 1 
of CRYZL1. The characteristics of the above­men­
tioned CpG-islands are specified in table 1. ITSN1/
CRYZL1 promoter analysis by RepeatMasker server 
has shown only one low complexity repeat of the 
G­rich subclass that comprises 71 bp before the an­
notated ITSN1 TSS.
Despite all these data the statement about the bidi­
rectionality of the ITSN1/CRYZL1 promoter requires 
further experimental confirmation.
The ITSN1-S isoform is expressed in all tissues. 
No significant difference was detected in different 
tissues or pathological states. The CRYZL1 gene is 
poorly investigated and there is no data about its ex­
pression at the moment. However, if the bidirection­
ality of the ITSN1/CRYZL1 promoter is confirmed, 
we may suppose that the CRYZL1 product is also 
ubiquitously expressed and is implicated in clathrin­
mediated endocytosis, cell signaling etc., as the 
genes transcribed from bidirectional promotes are 
often involved in the same cellular processes.
Besides the main ITSN1 promoter, one more alter­
native promoter is identified in intron 5. The nucleo­
tide sequence, which promoter activity was investi­
gated, is GC­rich. It has several consensuses that 
resemble TATA­box but all of them are non­func­
tional which is confirmed by the luciferase test with 
the deletion mutants of this region as well as by the 
presence of three TSS found by the 5’­RACE [21], 
that does not correlate with the presence of the func­
tional TATA­box [22]. The expression from the al­
ternative promoter was detected in most analyzed 
tissues, however, at the much lower level comparing 
to the main promoter [21]. The analysis of this re­
gion by the RepeatMasker server revealed LINE1­
repeat of the L1MC5 subclass, that is almost entirely 
located at the additional 5’­sequence before the exon 
6 which is crucial for the promoter activity and three 
SINE/Alu repeats (Table 2).
The ITSN1 gene is highly conservative. The bio­
informatics analysis of the ITSN1 intron 5 of seven 
organisms (Мacaca mulatta, Pan troglodytes, Bos 
taurus, Canis lupus familiaris, Rattus norvegicus, 
Мus musculus, Gallus gallus) for the repeat presence 
by the RepeatMasker server has shown that all of 
them have LINE1 repeat at the end of the intron 5. 
Moreover, only in chicken this repeat belongs to a 
CR1­H subclass repeat whereas in other organisms 
the repeats belong to L1МC5 was present in all 
other s.
Table 1. CpG islands of ITSN1/CRYZL1 promoter
Gene CRYZL1 ITSN1
Position* 33641571­33641951
33936694­
33937662
Band 21q22.11 21q22.11
Size CpG Island 381 969
CpG count 33 105
C count plus G count 246 624
Percentage CpG 17.3 % 21.7 %
Percentage C or G 64.6 % 64.4 %
Ratio of observed to expected 
CpG 0.85 1.05
* ­ the positions are according to the UCSC Genome Browser on 
Human Dec. 2013 (GRCh38/hg38) Assembly site.
Fig. 1. Schematic representation of the bidirectional promoter of the gene pair ITSN1/CRYZL1. Blue box represents the promoter 
sequence explored by Trinklein et. al. [15]; gray boxes indicate CpG­islands in the ITSN1 and CRYZL1 genes.
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Alternative splicing of the ITSN1 mRNA
According to the recent data, human genome compris­
es about 25 thousand genes [23], which encode several 
hundred thousands of protein molecules with the spe­
cific function. This is implemented by many mecha­
nisms the main of which are alternative splicing and 
alternative transcription. Alternative splicing is the 
process by which different pairs of splice sites are se­
lected to produce multiple transcripts from a single 
gene. It is controlled by the concerted action of multi­
ple cis­acting motifs and cognate trans­acting factors 
that promote or repress the assembly of productive 
splicing complexes (spliceosomes) at splice sites [24]. 
The EST analysis together with other bioinformatics 
computational methods revealed that minimum 70% 
of human genes have at least one alternatively spliced 
mRNA, and this proportion tends to increase [25].
ITSN1 gene has three main isoforms produced by 
alternative splicing with the attachment of three al­
ternative 3’UTR (Fig. 2). Thus, as a result of the se­
quential connection of 41 exons (excluding the exon 
30) the long isoform is produced which has a role in 
the specialized neuronal cell function and is ex­
pressed at high levels in these cells [26, 27, 28]. Its 
protein product comprises all eleven domains. As a 
result of the exon 30 splicing, a short isoform is 
formed, which is ubiquitously expressed and lacks 
three C­terminal domains (DH, PH, and C2). 
Recently described ITSN1-22a isoform is produced 
by the exon 22a splicing. It is expressed in all ana­
lyzed tissues. ITSN1­22a is the shortest isoform as it 
lacks seven C­terminal domains but includes 116 aa 
of disordered sequence instead. This sequence is re­
sponsible for the AMPH1 SH3 domain binding, al­
Table 2. The repeats in the human ITSN1 promoter regions identified by the RepeatMasker bioinformatics server
№
Position at the intron 5*
DNA strand Repeat name Repeat family
Position at the repeat
start end start end
1 13354 13686 + AluJo SINE/Alu 1 305
2 13778 14084 – AluJr4 SINE/Alu 2 306
3 14157 14465 + AluSx1 SINE/Alu 1 310
4 14484 14772 – L1МC5 LINE/L1 7108 6843
* ­ position is represented according to the numeration from 1 to 14938 of the intron 5 nucleotides.
lows formation of homodimers and dimers with 
ITSN1­S, and regulates ITSN1 interaction with the 
ubiquitin ligase CBL [29].
The ITSN1 expression from the above­mentioned 
alternative promoter leads to the formation of the 
isoforms lacking the first EH domain. However, the 
existence of these isoforms at the protein level has 
not been proved yet.
Besides the alternative splicing of the 5’­ and 3’­
ends, five in-frame splicing events are described for 
ITSN1, which change the amino acid composition of 
the protein (Fig. 2). The exon 20 splicing, which 
adds 15 bp coding 5 aa (VKGEW) in SH3A domain, 
is neuron-specific, and is controlled by nSR100/
SRRM4 (vertebrate- and neural-specific Ser/Arg re­
peat­related protein of 100 kDa) splicing regulator 
[30]. The exon 20 splicing is the most studied from 
these ITSN1 in­frame splicing events. It is known 
that the amount of its transcripts is gradually in­
creased during embryonic development [31]. It is 
also shown that in mouse neurons both (+20 exon) 
and (–20 exon) isoforms are expressed. It was de­
mon strated that inclusion of five amino acids in­
creases N­SRC loop of the SH3A domain, which in 
turn regulates the interaction strength of SH3A with 
DNM1, CdGAP, SOS1 and c­CBL. Previously, the 
human glioblastoma cell line U­251 MG has been 
tested by RT­PCR for the presence of the exon 20 
transcripts, but only isoforms lacking the exon 20 
were detected [32]. Its expression in other cell lines 
and tumors was not investigated. We decided to 
check the presence of these isoforms in cancer tis­
sues of different types. Interestingly, we have re­
vealed that the amount of the exon 20­containing 
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transcripts is decreased at different stages in the 
brain cancer specimen which could be explained by 
the decrease of neuron number in tumors. We have 
not detected the ITSN1 exon 20 containing isoforms 
either in renal  or in ovarian tissues (Fig. 3 A-I, B).
Four more in-frame alternative splicing events de­
scribed for ITSN1 are the following (Fig. 2):
1) 5’­truncation of exon 6 which leads to the 37 aa 
shortening of the spacer between EH1 and EH2;
2) excision of the exons 25 and 26 which leads to 
the loss of the SH3C domain;
3) excision of exon 35 (ITSN1-L∆35) which re­
sults in 25 aa truncation of the DH domain and short­
ening of the linker between DH and PH domains;
4) excision of exon 36 which leads to the PH do­
main loss.
The functional consequences of these alternative 
splicing events are currently unknown. We may 
suppose that the shortening of EH1­EH2 spacer and 
the SH3C domain loss lead to the conformational 
chan ges which serve to regulate the interaction of 
EH and SH3 domains with their partners; whereas 
the excision of the exons 35 and 36 most likely reg­
ulate the guanine­nucleotide exchange activity of 
the DH domain. The combination of all the above­
mentioned alternative splicing events seems to be 
sporadic. Thus, for the  isoform  ITSN1-S  all the 
reading frame combinations were cloned. For the 
ITSN1-L and alternative promoter isoforms only a 
few variants were obtained by cloning but this can 
be explained by cloning difficulties due to the big 
size of the products and/or their low expression. The 
expression of different transcripts significantly var­
ies. For instance, the transcripts with the exon 6 
truncation and the exon 36 excision make 3–5 % of 
total transcripts, whereas the transcripts with the ex­
ons 25–26 or the exon 35 excision make 20 % and 
10 % respectively [11].
The expression analysis of ITSN1-L and 
ITSN1-L∆35 isoform in different cancer types has 
shown the reduced transcripts number in brain tu­
mors which is consistent with the results for exon 20 
and can be explained by the same reasons (Fig. 3 
A­II, C). Interestingly, these isoforms, previously 
considered as ‘neuron-specific’, were also detected 
in the non­neuronal tumors. Thus, the ITSN1-L and 
ITSN1-L∆35 isoform transcripts were found in pheo­
chromocytome, breast and prostate cancer samples 
(Fig. 4 A-I). Moreover, we have observed that in 
several samples of various glioblastoma stages, as 
well as pheochromocytome, breast and prostate can­
cers the ratio between ITSN1-L and ITSN1-L∆35 
transcripts was changed with the preference for the 
latter (Fig. 3 D, Fig. 4 C, F, I). However, there were 
no significant changes in isoform 22a and transcripts 
with or without the exons 25–26 exons expression 
(Fig. 3 A-III, IV). Thus, we can assume that cancer 
interferes with the alternative splicing mechanisms, 
which in particular lead to the changes in ITSN1 iso­
forms ratio.
Fig. 2. Schematic representation of ITSN1 domain structure and alternative splicing events in human. Exon numbering is according 
to NM_003024.2. Asterisks indicate stop codons.
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Previously we have demonstrated the expression 
of ITSN1-L in the cancer cell lines MDA­MB­231 
and MCF-7 [5, 33]. Here we have shown by immu­
noprecipitation that ITSN1-L was expressed at the 
protein level in MDA­MB­231, a cancer cell line 
with invasive phenotype. We have used specific an­
tibodies to the ITSN1 DH domain which bind only 
ITSN1­L isoform. ITSN1­L was detected with anti­
ITSN1­EH antibodies in the precipitates obtained 
with anti­ITSN1­DH antibodies from the lysate of 
MDA-MB-231 cells (Fig. 5).
Besides the above­mentioned alternative splicing 
events which lead to the amino acid changes in 
ITSN1 composition, a variety of alternative splicing 
events causing the frame shift with the early stop­
codon appearance were described. Such transcripts 
are most likely degraded via nonsense­mediated 
mRNA decay (NMD) [11, 31].
To date there is no evidence on regulation of 
ITSN1 at mRNA level by changes in RNA transcrip­
tion from promoters in various tissues and under 
various physiological states. Considering the previ­
ous data and our results we can suppose that the 
regulation of ITSN1 alternative isoforms quantity is 
probably performed via different splicing factors to­
gether with the mRNA stability control.
Fig. 3. Analysis of ITSN1 isoforms expression: A: I – isoforms ITSN1 containing the exon 20 using primers specific for the exons 20 
(forward 2566­2587) and 23 (reverse 3184­3166); II – ITSN1-L and ITSN1-L∆35 using primers specific for the exons 34 (forward 
4394­4416) and 39 (reverse 5100­5122); III – isoforms ITSN1 with or without the exons 25-26 using primers specific for the exons 
23 (forward 3112­3135) and 27 (reverse 3509­3530); IV – containing the exon 22a using primers specific for the exons 22 (forward 
2583­2606) and 22a (reverse 2868­2891); V – analysis of expression of control gene β-actin. B: relative expression level of isoforms 
containing the exon 20; C: relative expression level of ITSN1-L and ITSN1-L∆35 isoforms; D: portion of ITSN1-L∆35 from total 
ITSN1-L isoforms expression. Densitometric measurements were performed using ImageJ software. NB – normal brain, GB – glio­
blastoma, A – astrocytoma, RT – renal tumor, NK – normal kidney, OV – overy tumor
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Prediction of microRNA target sites in 3`UTR 
of ITSN1
Despite the ITSN1 importance for endocytic process 
there is a limited information about its regulation at 
the post­transcriptional level by microRNAs (miRs). 
MicroRNAs are small non­coding RNA molecules 
18–25 nt long that regulate post­transcriptionally 
more than 1/3 of known genes [34]. In animals and 
Fig. 4. Analysis of expression of ITSN1-L and ITSN1-L∆35 isoforms in breast cancer, prostate cancer and pheochromocytoma: A, D, 
G: I – ITSN1-L and ITSN1-L∆35 using primers specific for the exons 33 (forward 4160-4182) and 41 (reverse 5307-5285); II – 
analysis of expression of control gene GAPDH – 983 bp or β-actin – 500 bp. B, I, H: relative expression level of ITSN1-L and ITSN1-
L∆35 isoforms; C, F, I: portion of ITSN1-L∆35 from total ITSN1-L isoforms expression. Densitometric measurements were per­
formed using ImageJ software. NT – normal tumor, T – tumor.
211
Transcriptional and post­transcriptional regulation of the adaptor/scaffold protein gene ITSN1 
humans mature miRs bind to the complementary 
sites in 3’­untranslated regions (3’UTRs) of their 
target mRNAs by 6–8 nt “seed” region on miRs 5’­
end thus negatively regulating gene expression [35]. 
Such mechanism is consi dered as main miR action. 
However, there is growing evidence of the positive 
regulation of gene expression as a result of miRs 
binding to the 5’UTRs or even protein coding re­
gions of target mRNAs [36].
As described above, human ITSN1 has three main 
isoforms with alternative 3’UTRs – ITSN1-L, 
ITSN1-S and ITSN1-22а, with 3’UTRs length of 
11566 nt, 1510 nt и 71 nt, respectively. [11, 29]. 
Despite the ITSN1 importance for endocytic process 
there is limited information about its regulation on 
post­transcriptional level by microRNAs. Currently, 
only one clear evidence of the ITSN1 post­transcrip­
tional regulation expression is known: Lin et al 
showed negative changes in the ITSN1­S expression 
by miR­194 [37]. According to the comparatively 
long 3’UTRs of main ITSN1 isoforms and their in­
volvement into several cellular processes it would 
have been intriguing if ITSN1 contains any other po­
tential microRNA sites. To study this we used bioin­
formatical prediction methods as a fast way to ana­
lyze 3’UTR and narrow our search. Targetscan ser­
vice is based on the search of target sites, which 
match the seed region of miRNAs, according to the 
site context and conservation, and known as one of 
the most accurate predictive servers [38, 39]. Thus, 
we used TargetScan v7.0 (August 2015 release) [39] 
as the main service for microRNA sites prediction in 
3’UTRs of ITSN1 isoforms. We took into account 
only highly conservative microRNA target sites 
based on the prediction for several species including 
human, mouse, rat, chicken, and tropical frog. 
The computational prediction of target sites in 
3’UTR of ITSN1-S mRNA (GenBank ID 
NM_001001132, Ensembl ID ENST00000399352.1) 
revealed the unique conservative sites for more than 20 
different microRNA families (Table 3). Among them, 
miR­19 family of microRNAs predicted to interact 
with two sites in 3’UTR of ITSN1-S located at 304–311 
nt and 752–759 nt downstream from the start of 3’UTR, 
respectively; miR­181/4262 family micro RNAs could 
bind two different sites  located at 1013–1019 nt and 
1405–1412 nt downstream from the start of 3’UTR. 
The only confirmed site for miR-194 is predicted as 
well. To refine our search we used MicroRNA.org, 
which is another web­service for  the microRNA target 
sites prediction [40, 41]. MicroRNA.org confirmed 
most of the sites predicted by TargetScan (Table 3). 
MicroRNA sites predicted by MicroRNA.org but not 
identified by TargetScan may have less  conservation 
thereby classified by TargetScan as less conservative 
and are excluded from our initial search. The obtained 
results indicate the factual existence of sites predicted 
above by TargetScan although further experimental 
verification is still needed.
On the contrary to ITSN1-S with 3’UTR of 1510 nt 
and 19 predicted different sites for more than 20 miR 
families, the brain-specific ITSN1-L isoform is char­
acterized by an extremely long 3’UTR of 11561 nt 
[11] with only few predicted microRNA target sites. 
Bioinformatical analysis by TargetScan v.7.0 identi­
fied only five conserved sites for microRNAs includ­
ing site for the miR­30 family, which is the only com­
mon site for both main ITSN1 isoforms (Table 4). 
MicroRNA.org did not find any of the above-men­
tioned microRNAs while some other sites were iden­
tified. This could be explained by usin g ITSN1-L iso­
Fig. 5. Endogenous ITSN1-L expression in invasive cancer cells. 
Lysates of MDA­MB­231 cells were subjected to immunopre­
cipitation using anti­ITSN1­DH antibodies and mouse IgG as a 
control. The precipitated proteins were eluted with Laemmli 
sample buffer and analyzed by Western blotting (WB). ITSN1L 
was detected using anti­ITSN1­EH antibodies.
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Table 3. MicroRNA target sites predicted for ITSN1-S (NM_001001132; ENST00000399352.1) by TargetScan v.7.0 
and MicroRNA.org
MicroRNA Target Sites Position of target sites in 3’UTR ITSN1-S according to TargetScan v. 7.0§
Position of target site in 3’UTR ITSN1-S 
according to MicroRNA.org§
miR­193a­5p 46–52; 411–418 –
miR­190a­5p/190b 59–65 –
miR-34ac-5p/449a/449b-5p 64–70 67–70
miR­326/330­5p 69–75** 68–75
miR-150-5p 82–88 82–88
miR­224­5p 104–110*** 106–113; 382–388
let-7a-g-5p/98-5p/miR-4458/4500 164–170 164–170
miR­202­3p 164–170**** 164–170
miR­371­5p 199–205*** 199–205
miR-10ab-5p 246–253 246–253
miR-19ab-3p 304–311; 752–759 304–311; 752–759
miR­590­3p 230–236; 329–336**** 329–336
miR­320a­d – 355–361
miR-129-5p 406–412 229–235; 406–412
miR-103a-3p/107 429–436 428–435
miR­26ab/1297 – 477–483
miR-141-3p/200a-3p 502–509 502–508
miR­487b 717–723*** 716–724
miR-194-5p 937–944 937–944
miR­375 – 987–993
miR-181a-d-5p/4262 1013–1019; 1405–1412 1013–1019; 1404–1412
miR­92ab – 1032–1038
miR­534 – 1046–1052
miR-30a-e-5p 1048–1055 1046–1054
miR­128 – 1069–1074
miR­140­3p.1 1069–1075 –
miR­136 1096–1102** 1095–1103
miR­214 1189–1195**** 1187–1196
miR­15ab/16/195/424/427 1191–1197* 1191–1198
miR­218­5p 1230–1237 –
miR­488 316–322; 1335–1341*** 1335–1342
miR­130ab/301ab/454 1380–1386* 1382–1389
miR-200bc-3p/429 1388–1394 1388–1395
miR­101­3p.2 1447–1453 –
The sites with high conservation predicted by both servers are bolded. Conservation was indicated according to TargetScan v.7.0. For 
sites predicted by MicroRNA.org levels of conservation were not mentioned. Positions for sites complementary to seed regions of 
respective microRNAs are indicated. § – positions of predicted binding sites are showed according to nucleotide numbering from the 
3’UTR first nucleotide of ITSN1-S from GenBank database, * – sites for poorly conserved miRNA families broadly conserved 
among vertebrates, ** – sites for conserved miRNA families conserved among mammals, *** – sites for poorly conserved miRNA 
families conserved among mammals, **** – sites for poorly conserved miRNA families. 
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Table 4. MicroRNA target sites predicted for ITSN1-L (NM_003024; ENST00000381318.3) by TargetScan v.7.0 
and MicroRNA.org
MicroRNA Target Sites Position of target sites in 3’UTR ITSN1-L according to TargetScan v. 7.0§
Position of target site in 3’UTR 
ITSN1-L according to MicroRNA.org§
miR­125a­5p/125­b – 17–24
miR­134 99–106*** 100–107
miR­28­5p/708 139–146*** 139–146
miR­384 144–150; 6744–6750*** 145–152
miR­219­5p 159–165* 161–168
miR­876­5p 259–265*** 261–268
miR­340 345–351; 3697–3703*** 345–351
miR­33ab 351–357; 4998–5004* 351–357
miR­25/32/92ab/363/367 3779–3785* 353–359
miR­342­3p 451–457*** 451–458
miR­185 502–508; 3338–3345*** 504–511
miR­103/107 518–524* 517–525
miR­300/381 643–649; 2258–2264; 3502–3509; 4298–4303*** 642–650
miR­199ab­5p 670–676; 784–790* 670–677
miR­615­3p 856–863*** 856–863
miR­181a­d 915–921; 1514–1520; 4905–4911; 10967–10973* 914–922
miR-203-3p.1 944–951*; 1605–1612 944–952
miR­653 948–954; 10444–10450**** 949–957
miR­135ab 979–985; 6011–6017* 976–986
miR­30­5p 1601–1607 –
miR­137 8527–8534 –
miR­216­5p 9417–9424 –
miR­182­5p 11118–11125 –
The sites with high conservation predicted by both servers are bolded. Conservation was indicated according to TargetScan v.7.0. For 
sites predicted by MicroRNA.org levels of conservation were not mentioned. Positions for sites complementary to seed regions of 
respective microRNAs are indicated. § – positions of predicted binding sites are showed according to nucleotide numbering from the 
3’UTR first nucleotide of ITSN1-L from GenBank database, * – sites for poorly conserved miRNA families broadly conserved 
among vertebrates, ** – sites for conserved miRNA families conserved among mammals, *** – sites for poorly conserved miRNA 
families conserved among mammals, **** – sites for poorly conserved miRNA families.
Table 5. Sites for regulatory elements in canonical and alternative 5’UTRs of ITSN1, predicted by RegRNA 2.0 web server
Canonical 5’UTR Alternative 5’UTR 
Type of Regulatory Element
Position of predicted sites for 
regulatory elements in 5’UTR 
according to RegRNA 2.0§
Type of Regulatory Element
Position of predicted sites for 
regulatory elements in 5’UTR 
according to RegRNA 2.0*
u1056_DISC2­RNA 5–33 u3712_snoRNAU1995_snoRNA
225–246
225–246
hsa­miR­149­3p 153–174 – –
§ – positions of predicted binding sites are shown according to the nucleotide numbering of canonical 5’UTR from GenBank data­
base; * – positions of predicted binding sites are shown according to the nucleotide numbering of alternative 5’UTR.
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Residue Location Tissue (Condition)
Ser203 EH1­EH2 
linker
HeLa cells [52]
Breast and ovarian cancer [53]
HMLER cells [54]
Jurkat cells [55]
K562 cells [45]
Breast cancer cells [56]
Muscle [57]
A498 cells [58]
Ser313 EH2­CCR 
linker
HeLa cells [52]
Non­small lung cancer cells [56]
Liver [59]
Jurkat cells [60]
Ser315 EH2­CCR 
linker
HeLa cells [52]
Breast and ovarian cancer (Re­
gulated by cold ischemia) [53]
HMLER cells [54]
Jurkat cells [60]
Lung tumor [61]
293E cells [62]
HeLa cells [45]
293 cells [63]
Ser318 EH2­CCR 
linker Liver [64]
Ser324 EH2­CCR 
linker Liver [64]
Thr349 EH2­CCR 
linker
In vitro (Ca2+/calmodulin­
dependent) [42]
Ser559 CCR HeLa cells [52]
Breast and ovarian cancer (Re­
gu lated by cold ischemia) [53]
Non­small lung cancer cells [56]
[55]
293 cells [65]
HeLa cells [66]
Ser564 CCR Liver [64]
Thr567 CCR In vitro (Ca2+/calmodulin­
dependent) [42]
Residue Location Tissue (Condition)
Ser624 CCR In vitro (Ca2+/calmodulin­
dependent) [42]
HeLa cells [52]
Basal breast cancer (Regulated 
by cold ischemia) [53]
HeLa cells [66]
Ser687 CCR Luminal breast cancer [53]
HeLa cells [66]
Ser735 CCR­SH3A 
linker HeLa cells [52]
Tyr749 SH3A HeLa cells [52]
Thr899 SH3A­
SH3B linker
Non­small lung cancer cells [56]
Liver [64]
HeLa cells [67]
Ser901 SH3A­
SH3B linker
Liver [64]
HeLa cells [52]
ovarian cancer [53]
HeLa cells [67]
293E cells [62]
GP293 cells (Transfected with 
NPM­ALK) [68]
Ser902 SH3A­
SH3B linker
HeLa cells (M­phase) [45]
Liver [64]
HeLa cells [52]
Non­small lung cancer cells, 
breast cancer cells [56]
Muscle [57]
Lung tumor [61]
293 cells [65]
HeLa cells [66]
GP293 cells (Transfected with 
NPM­ALK) [68]
Hela cells. K562 cells [45]
SKBr3 cells [69]
HUES­7 cells [70]
293 cells [63]
Table 6. Phosphorylation sites in human ITSN1 that were identified experimentally
form with incomplete 3’UTR of 1005 nt (GenBank 
ID NM_003024) instead of ITSN1-L with fully an­
notated 3’UTR (Ensembl ID ENST00000381318.3). 
At the same time, TargetScan could not predict any 
site found by MicroRNA.org at the region of 1005 nt 
downstream from the start of ITSN1-L 3’UTR. Such 
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Residue Location Tissue (Condition)
Ser904 SH3A­
SH3B linker
In vitro (Ca2+/calmodulin­
dependent) [42]
HeLa cells (G1 and M­phase) [45]
Liver [64]
HeLa cells (Cytosolic) [71]
HeLa cells [52]
ovarian cancer [53]
Non­small lung cancer cells, 
breast cancer cells [56]
Muscle [57]
A498 cells (LPA regulated) [58]
Jurkat cells [60]
Lung tumor [61]
293 cells [65]
HeLa cells [66]
Jurkat cells [55]
K562 cells [45]
SKBr3 cells [69]
293E cells [62]
HeLa cells [67]
Brain [72]
293 cells (AT1aR transfection) 
[73]
Liver [59]
U2OS cells [74]
HUES­7 cells [70]
hESCs [75]
293 cells [63]
WM115 cells [76]
Tyr922 SH3B 293 cells (AT1aR transfection) 
[73]
Ser970 SH3B Luminal breast cancer [53]
Ser976 SH3B­
SH3C linker
HeLa [52]
Breast and ovarian cancer 
(Regulated by cold ischemia) 
[53]
Thr977 SH3B­
SH3C linker
HeLa cells [52]
Non­small lung cancer cells [61]
Ser978 SH3B­
SH3C linker
In vitro (Ca2+/calmodulin­
dependent) [42]
Residue Location Tissue (Condition)
HeLa [52]
Muscle [57]
A498 cells [58]
Lung tumor [61]
Jurkat cells [55]
HeLa cells [67]
293 cells [63]
Ser981 SH3B­
SH3C linker
Liver [64]
HeLa cells [67]
Ser983 SH3B­
SH3C linker Lung tumor [61]
Ser984 SH3B­
SH3C linker HeLa cells [52]
Ser986 SH3B­
SH3C linker
HeLa cells (M­phase) [45]
HeLa cells [52]
Breast and ovarian cancer 
(Regulated by cold ischemia) 
[53]
HMLER cells [54]
Non­small lung cancer cells, 
breast cancer cells [56] 
HeLa cells [67]
293 cells [63]
K562 cells [45]
Ser989 SH3B­
SH3C linker
HeLa cells [52]
Luminal breast cancer [53]
Non­small lung cancer cells [56]
HeLa cells [67]
Ser995 SH3B­
SH3C linker Liver [64]
Ser1137 SH3D HeLa cells [52]
Breast and ovarian cancer [53]
Jurkat cells [55]
HeLa cells [45]
Brain [72]
Thr1144 SH3D­
SH3E linker
Liver [64]
HeLa cells [52]
Luminal breast cancer [53]
Jurkat cells [55]
Tyr1208 SH3E HeLa cells [52]
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results suggest an insufficient conservation of sites 
predicted by MicroRNA.org combined with some­
what different algorithms of prediction utilized by 
TargetScan and MicroRNA.org, which can be critical 
for predicting less probable sites.
In addition to the canonical impact of microRNAs 
on their targets as gene expression inhibition after 
binding to 3’UTRs of target mRNA, there is growing 
evidence of identifying functional microRNA target 
sites in coding regions as well as 5’UTRs of certain 
mRNAs that could enhance translation of target genes 
[36]. To predict any putative target sites for microR­
NAs and other regulatory elements in 5’UTRs of hu­
man ITSN1 we used web server RegRNA 2.0 for find­
ing different types of regulatory elements. 5’UTRs of 
ITSN1-S and ITSN1-L are formed by first and second 
exons and each has the length of 268 nt. Since 5’UTRs 
of ITSN1-S and ITSN1-L are identical, the obtained 
data are applicable to both ITSN1 isoforms. The com­
putational analysis revealed two types of regulatory 
elements: the site for u1056_DISC2­RNA (sites for 
hybridization with different types of non­coding RNAs 
except microRNAs) and one site for the human mi­
croRNA hsa­miR­149­3p (without indicating the le vel 
of conservation for microRNA target site) (Table 5). 
The ITSN1 isoforms transcribed from the alternative 
promoter have an alternative 400 nt 5’UTR [11]. To 
check if there are any different regulatory elements in 
this 5’UTR, we also used RegRNA 2.0, which predict­
ed the sites for u3712_snoRNA and U1995_snoRNA, 
but did not find any microRNA target sites (Table 5). 
In addition to the above­mentioned alternative 
5’UTR, ITSN1 is known to have alternative splicing 
in the exons 1a and 1b leading to the insertions of 62 
or 125 bp in canonical 5’UTR (187 bp in sum). The 
isoforms with these two exons and their combina­
tions are expressed in the majority of analyzing tis­
sues [11]. For 187 bp insertion of the exons 1a and 
1b, the computational analysis by RegRNA 2.0 
showed no differences compared to the prediction 
for canonical 5’UTR of ITSN1. This suggests that, 
according to RegRNA 2.0, 187 bp insertion added 
no new sites for the regulatory elements in intact 
5’UTR sequence. 
Phosphorylation of ITSN1
Post-translational modifications are the common 
way of regulation or modulation of the protein func­
tions. Such modifications in the scaffold proteins can 
facilitate or inhibit the interaction with particular 
proteins, providing a mechanism for the control on 
molecular complex composition. 
Large­scale studies of proteomes from different 
human tissues revealed a number of the ITSN1 post­
translational modifications, the vast majority of 
which is phosphorylation of serine or threonine resi­
dues (data from PhophositePlus database). In addi­
tion, our group have recently identified 5 sites of the 
Ca2+/calmodulin­dependent serine/threonine phos­
phorylation within ITSN1 molecule [42]. However, 
either the functional roles of these phosphorylation 
events or the kinases, responsible for these modifica­
tions, have not been studies yet. The available data on 
phosphorylation of ITSN1 is summarized in Table 6.
It is known that the phosphorylation sites are pre­
dominantly located in the intrinsically disordered 
regions of proteins [43, 44]. As can be seen from the 
Table 6, in general, this is true for ITSN1 as well. 
However, the phosphorylated residues within the 
coiled­coil region, DH, PH and SH3 domains have 
also been detected. In addition, the difference in the 
nature of serine/threonine and tyrosine phosphoryla­
tion can be observed. Whereas the majority of ser­
ine/threonine phosphorylation sites are located with­
in the interdomain linkers, all the identified phos­
phorylated tyrosines belong exclusively to the SH3 
domains. These differences reflect a distinct distri­
bution of these amino acid residues in ITSN1 mole­
cule. As can be seen from the frequency plots, the 
serine/threonine residues are more abundant and 
tend to form serine/threonine­rich clusters in the in­
terdomain linkers, which are especially prominent in 
the EH2­CCR, SH3A­SH3B and SH3B­SH3C link­
ers (Fig. 6, middle panel). In contrast, the tyrosine 
residues are mostly individual and located within the 
structural domains (Fig. 6, lower panel). These dif­
ferences can reflect distinct functional roles of the 
tyrosine versus serine/threonine phosphorylation in 
the protein functions.
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It is not clear whether the identified ITSN1 phos­
phorylation sites are phosphorylated permanently or 
in   response to some conditions. We have shown that 
some kinases can phosphorylate ITSN1 in vitro in a 
Ca2+/calmodulin­dependent manner, but it is currently 
not clear if this occurs in living cells as well [42]. 
Also, several sites were shown to be phosphorylated 
in HeLa cells in specific phases of the cell cycle, indi­
cating their possible regulation by the cell cycle­de­
pendent enzymes [45]. In another study, ITSN1 was 
shown to undergo the tyrosine phospho rylation in 293 
cells in response to overexpression of tyrosine kinase 
Syk and Epstein­Barr virus protein LMP2A (Latent 
Membrane Protein 2A), but the sites of this phosphor­
ylation were not identified [46]. On the other hand, the 
ITSN1 tyrosine phosphorylation in response to EGF 
stimulation in several human cell lines has not been 
detected, in contrast to its paralog ITSN2 [33]. 
It is predicted that not all of the phosphorylated 
sites identified in the large-scale proteomic studies 
are functional [47]. Therefore, since no functional 
role was reported for any of the identified ITSN1 
phosphorylation sites, their functionality remains 
questionable. However, some possible outcomes 
from these phosphorylation events can be proposed. 
Several phosphorylation sites were identified within 
the coiled­coil region of ITSN1. It is known that the 
phosphorylation of threonine residues within coiled­
coils can destabilize helices, while the phorphoryla­
tion of serine residues can both stabilize or destabi­
lize them depending on the position [48, 49]. It can 
be expected that modifications in the coiled-coil re­
gions can affect their ability to oligomerize or to 
form complexes with similar domains in other pro­
teins. In support of this, it has been shown that the 
phosphorylation of coiled­coil region of the CRN2 
protein affects its interaction with actin regulatory 
proteins, leading to the alterations of actin architec­
ture and inhibition of the cell migration [50].
Most of the phosphorylation sites in the ITSN1 
molecule are located in the interdomain linkers that 
are suggested to be intrinsically disordered. For to­
day, the functions of ITSN1 interdomain linkers re­
main mostly unknown, although the linker between 
SH3A and SH3B domains was shown to interact with 
the α- and β-subunits of endocytic adapter protein 
AP2 [28]. Phosphorylation of the linkers indicates 
other potential functions of them. One possibility is 
Fig. 6. Phosphorylation of human ITSN1. Upper panel – schematic representation of domain structure of ITSN1 molecule. Middle 
panel – distribution of serine/threonine residues in ITSN1 molecule. Each value of Ser/Thr frequency was calculated as frequency of 
serine/threonine per frame of 10 amino acid residues. Ser/Thr phosphorylation sites are marked by triangles. Lower panel – distribu­
tion of tyrosine (Tyr) residues in ITSN1 molecule (presented in the same way as serine/threonine distribution).
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that the phosphorylation of interdomain linkers can 
modify their structure and alter mutual orientation of 
ITSN1 domains, thereby affecting a higher order 
structure of the molecular complexes formed by 
ITSN1. Alternatively, the phosphorylation of interdo­
main linkers can create new interfaces for the pro­
tein­protein interactions. In support of this, the ELM 
server predicts that the Ser978 phosphorylation cre­
ates a motif for interaction with the 14­3­3 proteins 
and the WW domains of Pin proteins. Intriguingly, 
two large clusters of serine/threonine residues direct­
ly surround the SH3B domain, thereby, it is likely 
that these regions could regulate the SH3B binding 
properties. This domain interacts with endocytic pro­
tein endophilin in a manner that is different from a 
canonical SH3 domain binding mode [51]. A poten­
tial role of phosphorylation in regulation of this and 
other interactions is a topic for further investigations.
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Транскрипційна та постранскрипційна регуляція гена 
адапторного/скафолдного білка ITSN1
С. В. Кропивко, O. С. Губар, T. A. Грязнова, 
Д. Е. Мордерер, Д. O. Герасимчук, Л. А. Сивак, 
О. М. Грабовий, A. В. Риндич.
ITSN1 – адаптерний/скафолдний білок який приймає участь 
у різноманітних фізіологічних та патологічних клітинних 
процесах. Він має складну регуляцію експресії та багаточи­
сельні білки партнери. Мета. Характеристика функціону­
вання та регуляції експресії ITSN1 має важливе значення 
для розуміння ролі ITSN1 в житті клітини. Методи. 
Біоінформатичний аналіз, напівкількісний аналіз експресії 
за допомогою ЗТ-ПЛР, іммунопреципітація. Результати. 
Ми описали та проаналізували промоторні регіони ITSN1, 
детектували альтернативно сплайсовані ізоформи ITSN1 на 
рівні мРНК та білка в різних зразках раку. За допомогою різ­
номанітних біоінформатичних серверів ми виявили сайти 
зв’язування з мікроРНК, а також ми проаналізували сайти 
серин-, треонін- та тирозин-фосфорилювання білка ITSN1. 
Висновки. Ми отримали нові дані про експресію ITSN1 при 
патологіях. Крім того, ми показали можливість регуляції 
экспресії ITSN1 за допомогою мікроРНК та ролі фосфори­
лювання серину, треоніну и тирозину в регуляції взаємодії 
ITSN1 з білками партнерами. 
К л юч ов і  с л ов а: ITSN1, двонаправлений промотор, аль­
тернативний сплайсинг, мікроРНК, фосфорилювання.
Транскрипционная и постранскрипционная регуляция 
гена адапторного/скафолдного белка ITSN1
С. В. Кропивко, O. С. Губарь, T. A. Грязнова, 
Д. Е. Мордерер, Д. А. Герасимчук, Л. А. Сивак, 
А. Н. Грабовой, A. В. Рындич.
ITSN1 – адапторный/скафолдный белок который принимает 
участие в различных физиологических и патологических кле­
точных процессах. Он имеет сложное регулирование экспрес­
сии и многочисленные белки партнеры. Цель. Характеристика 
функционирования и регуляция экспрессии ITSN1 имеет важ­
ное значение для понимания роли ITSN1 в жизни клетки. 
Методы. Биоинформатический анализ, полуколичественный 
анализ экспрессии с помощью ОТ-ПЦР, иммунопреципита­
ция. Результаты. Мы описали и проанализировали промотор­
ные области ITSN1, детектировали альтернативно сплайсиро­
ванные изоформы ITSN1 на уровне мРНК и белка в разных 
образцах рака. С помощью различных биоинформатических 
серверов мы определили сайты связывания с микроРНК, так­
же мы проанализировали сайты серин-, треонин- и тиро­
зин-фосфорилирования белка ITSN1. Выводы. Мы получили 
новые данные про экспрессию ITSN1 при патологиях. Кроме 
того, мы показали возможность регуляции экспрессии ITSN1 с 
помощью микроРНК и потенциальной роли фосфорилирова­
ния серина, треонина и тирозина в регуляции взаимодействия 
ITSN1 с белками партнерами.
К л юч е в ы е  с л ов а: ITSN1, двунаправленный промотор, 
альтернативный сплайсинг, микроРНК, фосфорилирование.
Received 08.05.2016
